ATAI
Ataibeckley Inc
NASDAQ · Pharmaceuticals
$3.77
+0.36 (+10.56%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 690.1K | 2.79M | 413.99M | 436.73M | 411.33M |
| Net Income | -338,516,021 | -1,232,461,241 | 66.80M | 64.85M | 60.17M |
| EPS | — | — | — | — | — |
| Profit Margin | -48,464.0% | -46,040.8% | 16.1% | 14.9% | 14.6% |
| Rev Growth | -75.3% | -75.3% | +2.9% | -6.2% | +4.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 115.06M | 115.06M | 118.79M | 135.87M | 139.90M |
| Total Equity | 569.60M | 569.60M | 555.67M | 567.13M | 542.89M |
| D/E Ratio | 0.20 | 0.20 | 0.21 | 0.24 | 0.26 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -327,292,689 | -1,257,799,573 | 114.08M | 102.81M | 96.57M |
| Free Cash Flow | — | — | 60.27M | 81.44M | 75.18M |